Analysis of Differential Proteins Related to Platelet Activation in Patients with Essential Thrombocythemia Based on Label-Free Quantitative Technology.
10.19746/j.cnki.issn.1009-2137.2022.03.028
- Author:
Yu-Jin LI
1
;
Ju-Ning MA
1
;
Zi-Qin WANG
2
;
Er-Peng YANG
1
;
Ming-Jing WANG
1
;
Jing MING
1
;
De-Hao WANG
2
;
Ji-Cong NIU
1
;
Wei-Yi LIU
3
;
Xiao-Mei HU
4
Author Information
1. Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
2. Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China.
3. Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China,E-mail: liuweiyi0530@hotmail.com.
4. Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China,E-mail: huxiaomei_2@163.com.
- Publication Type:Journal Article
- Keywords:
biological markers;
essential thrombocythemia;
platelet activation;
proteomics;
serum
- MeSH:
Blood Platelets/metabolism*;
Humans;
Platelet Activation;
Platelet Membrane Glycoproteins/metabolism*;
Technology;
Thrombocythemia, Essential
- From:
Journal of Experimental Hematology
2022;30(3):836-843
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analysis the specific protein markers of essential thrombocythemia (ET) based on proteomics technology, to explore and verify the differential protein related to platelet activation.
METHODS:Blood samples were obtained from ET patients and healthy people and a certain protein mass spectrometry was detected using label-free quantitative technology. The proteins relative abundance increased or down-regulated by 1.3 times in the disease group compared with the control group, and the protein abundance in the two groups t test P＜0.05 were defined as differential proteins. Bioinformatics analysis of the differential proteins was performed using GO and KEGG. The difference in the average protein abundance between the two groups was analyzed by t test and P＜0.05 was considered statistically significant. Differential proteins were selected for verification by parallel reaction monitoring (PRM) technology.
RESULTS:A total of 140 differential proteins were found, of which 72 were up-regulated and 68 were down-regulated. KEGG enrichment showed that the differential protein expression was related to the platelet activation pathway. The differential proteins related to platelet activation were GPV, COL1A2, GP1bα, COL1A1 and GPVI. Among them, the expressions of GPV, GP1bα and GPVI were up-regulated, and the expressions of COL1A2 and COL1A1 were down-regulated. PRM verification of COL1A1, GP1bα, GPVI and GPV was consistent with LFP proteomics testing.
CONCLUSION:Differential proteins in ET patients are related to platelet activation pathway activation.Differential proteins such as GPV, GPVI, COL1A1 and GP1bα can be used as new targets related to ET platelet activation.
